H.C. Wainwright raised the firm’s price target on Mineralys Therapeutics (MLYS) to $56 from $52 and keeps a Buy rating on the shares. The firm is “enthusiastic” as Mineralys heads towards the near-term application submission for its oral selective aldosterone synthase inhibitor candidate lorundrostat.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS: